Article Sidebar

Submitted
Jul 31, 2024
Published
Jul 31, 2024
Download
PDF
Statistic
Read Counter : 109 Download : 49

Main Article Content

Abstract

Alzheimer's disease (AD) is a progressive neurological disorder and the leading cause of dementia in the elderly. It is distinguished by memory loss, cognitive deterioration, and personality shifts. Despite substantial research, the pathophysiology of Alzheimer's disease is not fully understood, and viable treatments are missing. This review seeks to offer a complete overview of current AD knowledge, including epidemiology, pathophysiology, genetic and environmental risk factors, diagnostic criteria, and therapeutic approaches.

Keywords

Alzheimer's disease (AD) Dementia Amyloid-beta plaques Neuro fibrillary tangles Tau protein Neuro inflammation Cognitive decline, biomarkers Monoclonal antibodies

Article Details

How to Cite
G. Navya Reddy, Policepatel Vamshi Krishna, & Nomula Akhila Reddy. (2024). Understanding Alzheimer’s Disease: A Comprehensive Review. International Journal of Research in Pharmacology & Pharmacotherapeutics, 13(3), 273-279. Retrieved from https://ijrpp.com/ijrpp/article/view/556
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Alzheimer's Disease International. World Alzheimer Report 2019: Attitudes to dementia. Retrieved from [URL]
  2. 2. Alexander, G. C., Emerson, S., & Kesselheim, A. S. Evaluation of the FDA’s Approval of Aducanumab. JAMA, 2021; 325(17), 1717-1718.
  3. 3. Contestabile, A., Ciani, E., & Contestabile, A. Neuroprotection in Alzheimer's disease: From preclinical studies to clinical trials. Current Pharmaceutical Design, 2021; 27(2), 200-214.
  4. 4. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., et al., Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. New England Journal of Medicine, 2018; 378(18), 1691-1703.
  5. 5. Giacobini, E., & Becker, R. E. One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? Journal of Alzheimer's Disease, 2021; 81(2), 509-517.
  6. 6. Goedert, M., Spillantini, M. G., & Ghetti, B. Frontotemporal dementia: Implications for understanding Alzheimer's disease. Cold Spring Harbor Perspectives in Medicine, 2017; 7(1), a024539.
  7. 7. Groot, C., Hooghiemstra, A. M., Raijmakers, P. G., van Berckel, B. N., Scheltens, P., Scherder, E. J. & van der Flier, W.M. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Research Reviews, 2016; 25, 13-23.
  8. 8. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E. & Hardy, J. TREM2 variants in Alzheimer's disease. New England Journal of Medicine, 2013; 368(2), 117-127.
  9. 9. Heneka, M. T., Golenbock, D. T., & Latz, E. Innate immunity in Alzheimer's disease. Nature Immunology, 2015; 16(3), 229-236.
  10. 10. Iqbal, K., Liu, F., & Gong, C. X. Tau and neurodegenerative disease: the story so far. Nature Reviews Neurology, 2010; 6(12), 741-754.
  11. 11. Jack, C. R., Jr., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., ... & Trojanowski, J. Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology, 2011; 9(1), 119-128.
  12. 12. Jernerén, F., Cederholm, T., Refsum, H., Sahlin, C., Rasmussen, B. B., Blennow, K. & Smith, A. D. Homocysteine status and its relationship to brain magnetic resonance imaging measures in cognitively healthy elderly: The PIVUS study. Archives of Gerontology and Geriatrics, 2015; 61(4), 559-566.
  13. 13. Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D. & Sperling, R. A. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of Neurology, 2016; 79(1), 110-119.
  14. 14. Kim, J., Basak, J. M., & Holtzman, D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron, 2009; 63(3), 287-303.
  15. 15. Leng, F., & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nature Reviews Neurology, 2021; 17(3), 157-172.
  16. 16. Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S. & Mukadam, N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 2020; 396(10248), 413-446.
  17. 17. Loy, C. T., Schofield, P. R., Turner, A. M., & Kwok, J. B.Genetics of dementia. The Lancet, 2014; 383(9919), 828-840.
  18. 18. McShane, R., Areosa Sastre, A., & Minakaran, N. Memantine for dementia. Cochrane Database of Systematic Reviews, 2019; (2), CD003154.
  19. 19. Nikolich-Žugich, J., & Goldman, D. P. Personalized medicine and the future of health care in an aging world. The Journal of Clinical Investigation, 2020; 130(2), 536-539.
  20. 20. Porter, T., Palomo-Irigoyen, M., & Polacheck, W. J.Gene therapy for Alzheimer's disease: Developments, current challenges, and perspectives. Gene Therapy, 2020; 27(1), 67-78.
  21. 21. Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. World Alzheimer Report 2015: The global impact of dementia. Alzheimer's Disease International.
  22. 22. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M. & Sandrock,A. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 2016; 537(7618), 50-56.
  23. 23. Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C. & Trojanowski, J. Q. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's & Dementia, 2017; 13(4), e1-e85.
  24. 24. Xuan, A. G., Long, D. H., Gu, H. G., & Xu, Y. G. Stem cell therapy for Alzheimer's disease: current challenges and perspectives. Current Neuropharmacology, 2020; 18(4), 311-320.
  25. 25. Brinton, R.D. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends in Pharmacological Sciences, 2009; 30(4), 212-222.
  26. 26. Cuttler, J. M., & Sanders, C. L. Hypothesis: Alzheimer's disease is caused by protective failure of the brain microcirculation due to capillary aging. Journal of Alzheimer's Disease, 2017; 56(3), 1199-1211.
  27. 27. Smith, S. S., Meyer, M., & Webster, J. Estrogen, cognition, and a woman's aging brain. Frontiers in Neuroendocrinology, 2017; 45, 39-51.
  28. 28. Yao, J., Hamilton, R. T., Cadenas, E., & Brinton, R. D. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain aging: role of bioavailable estrogen. Neurobiology of Aging, 2010; 31(9), 1507-21.